Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles
Open accessThe DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Abstract
Targeted therapy of cancer using oncolytic viruses has generated much interest over the past few years in the light of the limited efficacy and side effects of standard cancer therapeutics for advanced disease. In 2006, the world witnessed the first government-approved oncolytic virus for the treatment of head and neck cancer. It has been known for many years that viruses have the ability to replicate in and lyse cancer cells. Although encouraging results have been demonstrated in vitro and in animal models, most oncolytic viruses have failed to impress in the clinical setting. The explanation is multifactorial, determined by the complex interactions between the tumor and its microenvironment, the virus, and the host immune response. This review focuses on discussion of the obstacles that oncolytic virotherapy faces and recent advances made to overcome them, with particular reference to adenoviruses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969 · cited 1×
“Nonetheless, targeting a single gene is unlikely to have a major impact on survival, given that in cancer a large number of genetic alterations affect only a core set of signaling pathways and processes, as has been recently described for pancreatic cancer [66].”
BackgroundHigh Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222 · cited 1×
“physical barrier to successful virus delivery and this effect increases with tumor volume [100].”
BackgroundAn Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760 · cited 1×
“E1B 55Kdeleted Ad could replicate in tumor selectively because of non-functioning p53 [31], cyclin”
BackgroundExperimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., & Bell, J. C. (2000) · Nature Medicine · doi:10.1038/77558 · Cited by 815 · cited 4×
“A study by Diaz et al. [135] revealed that depletion of regulatory T cells reduced the efficacy of oncolytic VSV, due to the relief of anti-viral immune response suppression.”
BackgroundInfluentialCD46 is a cellular receptor for group B adenoviruses
Gaggar, A., Shayakhmetov, D. M., & Lieber, A. (2003) · Nature Medicine · doi:10.1038/nm952 · Cited by 792 · cited 11×
“Besides CD46, evidence suggests that the subgroup B Ad, Ad11, also utilizes another unidentified receptor [121,122], tentatively named ‘receptor X’ by Tuve et al. [123].”
BackgroundInfluentialHistory of Oncolytic Viruses: Genesis to Genetic Engineering
Kelly, E., & Russell, S. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300108 · Cited by 763 · cited 1×
“The ability of viruses to kill cancer cells has been recognized for more than a century [1].”
BackgroundReovirus Therapy of Tumors with Activated Ras Pathway
Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. K. (1998) · Science · doi:10.1126/science.282.5392.1332 · Cited by 750 · cited 1×
“Inactivated IFN and activated Ras pathways are frequently found in cancer (the latter could inhibit PKR), and some naturally-found viruses can replicate selectively in cancer but not normal cells, including the Newcastle disease virus (NDV) [21], reovirus [22], vaccinia virus [23], and vesicular stomatitis virus (VSV)…”
BackgroundAdenovirus Serotype 5 Hexon Mediates Liver Gene Transfer
Waddington, S. N., McVey, J. H., Bhella, D., Parker, A. L., Barker, K., Atoda, H., Pink, R., Buckley, S. M. K., Greig, J. A., Denby, L., et al. (2008) · Cell · doi:10.1016/j.cell.2008.01.016 · Cited by 643 · cited 1×
“[174] showed that liver transduction is mediated by interaction of the adenoviral hexon protein with the blood coagulation factor X.”
BackgroundAn adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., & Kirn, D. (2000) · Nature Medicine · doi:10.1038/80474 · Cited by 583 · cited 2×
“Because cancer cells are often in the S phase, E1A CR2-deleted Ad5 mutant (dl922-947) could selectively replicate in and destroy replicating cancer cells but not normal resting cells [29].”
BackgroundHecht, J. R., Bedford, R. A., Abbruzzese, J. L., Lahoti, S., Reid, T. R., Soetikno, R. M., Kirn, D. H., & Freeman, S. M. (2003) · Clinical Cancer Research · Cited by 552
Ganly, I., Kirn, D. H., Eckhardt, G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C. C., et al. (2000) · PubMed · Cited by 508
Innate Immune Mechanisms Dominate Elimination of Adenoviral Vectors Following In Vivo Administration
Worgall, S., Wolff, G., Falck-Pedersen, E., & Crystal, R. G. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.1-37 · Cited by 491 · cited 1×
“It appears that the innate immune response plays an important role in virus clearance, whereas T cell-mediated responses are largely responsible for the anti-tumoral effect [133-137].”
BackgroundChina Approves World's First Oncolytic Virus Therapy For Cancer Treatment
Garber, K. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj111 · Cited by 489 · cited 1×
“In 2005, an adenovirus (Ad) with E1B 55K gene deletion (H101(Oncorine); Shanghai Sunway Biotech, Shanghai, China) was approved in China as the world’s first oncolytic virus for head and neck cancer in combination with chemotherapy [3].”
BackgroundNemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.289 · Cited by 471 · cited 1×
“This virus was the first engineered, replicating Ad to enter clinical trials for cancers including those of the head and neck [43-45] and pancreas [46,47].”
BackgroundNemunaitis, J. J., Ganly, I., Khuri, F. R., Arseneau, J. C., Kuhn, J., McCarty, T. M., Landers, S., Maples, P. B., Romel, L., Randlev, B., et al. (2000) · PubMed · Cited by 462
Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers
Peng, Z. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1016 · Cited by 436 · cited 1×
“known example is Gendicine (Shenzhen SiBiono GeneTech, Shenzhen, China), an Ad5 vector encoding the human TP53 gene that was approved in 2004 by China’s State Food and Drug Administration for the treatment of head and neck cancer [63].”
BackgroundBlood clearance rates of adenovirus type 5 in mice
Alemany, R., Suzuki, K., & Curiel, D. T. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-11-2605 · Cited by 413 · cited 1×
“After intravenous delivery the liver, part of the reticuloendothelial system, is the predominant site of Ad5 sequestration with significant hepatocyte transduction [171,172].”
BackgroundTargeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402 · cited 2×
“Gene-manipulated oncolytic viruses such as Ad, herpes virus and vaccinia virus are being developed as a new class of anti-tumoral agent [23,40,41].”
BackgroundFishelson, Z. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(03)00112-3 · Cited by 400 · cited 1×
“In contrast, most subgroup B Ads bind to CD46 [110], a receptor often upregulated in a number of tumor types, including breast, cervical, liver, lung, endometrial and hematological malignancies [111-113].”
BackgroundLate viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity
O'Shea, C. C., Johnson, L., Bagus, B., Choi, S., Nicholas, C., Shen, A., Boyle, L., Pandey, K., Soria, C., Kunich, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.11.012 · Cited by 372 · cited 1×
“E overexpression [32], and E1B 55K-independent late viral RNA export in cancer but not normal cells [33].”
BackgroundSumida, S. M., Truitt, D. M., Lemckert, A. A. C., Vogels, R., Custers, J. H. H. V., Addo, M. M., Lockman, S., Peter, T., Peyerl, F. W., Kishko, M. G., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7179 · Cited by 369 · cited 1×
“These antibodies are mainly directed against the viral hexon proteins [156], suggesting that the use of Ad11 virion might be better than chimeric Ad5/11, where the fibers are derived from Ad11 but the rest, including hexon, belong to Ad5.”
BackgroundCyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
Fulci, G., Breymann, L., Gianni, D., Kurozomi, K., Rhee, S. S., Yu, J., Kaur, B., Louis, D. N., Weissleder, R., Caligiuri, M. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605496103 · Cited by 357 · cited 1×
“One method is by using an immunosuppressive agent, such as cyclophosphamide, that has been shown to improve virus spread and anti-tumoral efficacy [139-145].”
MethodHan, J., Sabbatini, P., Perez, D., Rao, L., Modha, D., & White, E. (1996) · Genes & Development · doi:10.1101/gad.10.4.461 · Cited by 349 · cited 5×
“In addition to its effect on virus release and Viruses 2010, 2 83 spread [51,52], adenoviral E1B 19K is a functional homolog of Bcl-2 and is able to bind to Bax [53-55] and also prevent Fas-mediated apoptosis [56].”
BackgroundInfluentialIkeda, K., Ichikawa, T., Wakimoto, H., Silver, J. S., Deisboeck, T. S., Finkelstein, D., Harsh, G. R., Louis, D. N., Bartus, R. T., Hochberg, F. H., et al. (1999) · Nature Medicine · doi:10.1038/11320 · Cited by 339 · cited 1×
“Various data suggest that pre-existing antibodies decrease virus spread after intravenous delivery [147-149], but have a lesser effect on intratumoral injection [44,150,151].”
BackgroundHuard, J., Lochmüller, H., Acsádi, G., Jani, A., Massie, B., & Karpati, G. (1995) · PubMed · Cited by 331
High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus
Anderson, B. D., Nakamura, T., Russell, S. J., & Peng, K.-W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0884 · Cited by 315 · cited 1×
“, Coxsackievirus A21 [12] and measles virus (MV) [13]) or have been designed to have specific tropism based on the”
BackgroundAdenovirus-5 E1A: paradox and paradigm
Frisch, S. M., & Mymryk, J. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm827 · Cited by 308 · cited 1×
“The adenoviral E1A is the earliest gene to be transcribed after virus entry into the host cell [50].”
BackgroundMesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses
Komarova, S., Kawakami, Y., Stoff-Khalili, M. A., Curiel, D. T., & Pereboeva, L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0334 · Cited by 302 · cited 1×
“Cells that have been tested include mesenchymal stem cells [157-159],”
BackgroundMulvihill, S., Warren, R., Venook, A., Adler, A., Randlev, B., Heise, C., & Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301398 · Cited by 299 · cited 1×
“This virus was the first engineered, replicating Ad to enter clinical trials for cancers including those of the head and neck [43-45] and pancreas [46,47].”
BackgroundNemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301424 · Cited by 283 · cited 1×
“Whilst the virus has shown good tumor selectivity and safety [48], durable objective responses with this virus as a single agent have been limited and this could be partly due to the loss of other essential functions of the E1B 55K and E3B genes.”
BackgroundJiang, H., Gomez-Manzano, C., Aoki, H., Alonso, M. M., Kondo, S., McCormick, F., Xu, J., Kondo, Y., Bekele, B. N., Colman, H., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm102 · Cited by 278 · cited 1×
“Evidence has shown that oncolytic Ads are able to destroy these cells [129-131].”
BackgroundOncolytic Immunovirotherapy for Melanoma Using Vesicular Stomatitis Virus
Diaz, R. M., Galivo, F., Kottke, T., Wongthida, P., Qiao, J., Thompson, J., Valdes, M., Barber, G., & Vile, R. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3974 · Cited by 264 · cited 2×
“It appears that the innate immune response plays an important role in virus clearance, whereas T cell-mediated responses are largely responsible for the anti-tumoral effect [133-137].”
BackgroundMesenchymal Stem Cells Effectively Deliver an Oncolytic Adenovirus to Intracranial Glioma
Sonabend, A. M., Ulasov, I. V., Tyler, M. A., Rivera, A. A., Mathis, J. M., & Lesniak, M. S. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0758 · Cited by 254 · cited 1×
“Cells that have been tested include mesenchymal stem cells [157-159],”
BackgroundShafren, D. R., Dorahy, D. J., Ingham, R. A., Burns, G. F., & Barry, R. D. (1997) · Journal of Virology · doi:10.1128/jvi.71.6.4736-4743.1997 · Cited by 243
Reddy, P. S., Burroughs, K. D., Hales, L. M., Ganesh, S., Jones, B. H., Idamakanti, N., Hay, C., Li, S. S., Skele, K. L., Vasko, A.-J., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm198 · Cited by 242 · cited 1×
“As continuing work is being done to improve the currently available oncolytic viruses, novel viral species are also emerging and worth exploring, for example the porcine Seneca Valley virus [203], myxoma virus [204], Sindbis”
BackgroundTOLLEFSON, A. E., RYERSE, J. S., SCARIA, A., HERMISTON, T. W., & WOLD, W. S. M. (1996) · Virology · doi:10.1006/viro.1996.0295 · Cited by 231 · cited 1×
“6K (or adenovirus death protein – ADP), which facilitates late cytolysis of infected cells and release of progeny viruses [60].”
BackgroundEngineering microRNA responsiveness to decrease virus pathogenicity
Kelly, E. J., Hadac, E. M., Greiner, S., & Russell, S. J. (2008) · Nature Medicine · doi:10.1038/nm.1776 · Cited by 217 · cited 1×
“This has been demonstrated by several groups [34-38].”
BackgroundCarlisle, R. C., Di, Y., Cerny, A. M., Sonnen, A. F.-P., Sim, R. B., Green, N. K., Subr, V., Ulbrich, K., Gilbert, R. J. C., Fisher, K. D., et al. (2009) · Blood · doi:10.1182/blood-2008-09-178459 · Cited by 204
Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus
Kirn, D. H., Wang, Y., Le Boeuf, F., Bell, J., & Thorne, S. H. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040353 · Cited by 203 · cited 1×
“[189] utilized this mutant and inserted a gene that encodes IFN-β (which itself has anti-proliferative, anti-angiogenic, and immunomodulatory antitumoral effects), and demonstrated enhanced tumor selectivity and potency in vivo.”
Self-citationThorne, S. H., Hwang, T.-H. H., O’Gorman, W. E., Bartlett, D. L., Sei, S., Kanji, F., Brown, C., Werier, J., Cho, J.-H., Lee, D.-E., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32727 · Cited by 202 · cited 1×
“encoding for both thymidine kinase and VGF leads to further selectivity of vaccinia virus in cancers with an activated EGFR-Ras pathway [4].”
BackgroundSelf-citationCarrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity
Power, A. T., Wang, J., Falls, T. J., Paterson, J. M., Parato, K. A., Lichty, B. D., Stojdl, D. F., Forsyth, P. A. J., Atkins, H., & Bell, J. C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300039 · Cited by 191 · cited 1×
“[168] tested a number of carrier cells including solid tumor and leukemic cells, and demonstrated that the efficacy of oncolytic vesicular stomatitis virus (VSV) was significantly improved compared to naked virion injection.”
BackgroundWhitley, R. J., Kern, E. R., Chatterjee, S., Chou, J., & Roizman, B. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116527 · Cited by 188 · cited 1×
“5 (RL1) results in selective replication in tumors with a defective IFN/PKR pathway [25].”
BackgroundStem Cell Collection and Gene Transfer in Fanconi Anemia
Kelly, P. F., Radtke, S., Kalle, C. V., Balcik, B., Bohn, K., Mueller, R., Schuesler, T., Haren, M., Reeves, L., Cancelas, J. A., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300033 · Cited by 180
Researchers and regulators reflect on first gene therapy death
Hollon, T. (2000) · Nature Medicine · doi:10.1038/71545 · Cited by 175
Qiao, J., Wang, H., Kottke, T., White, C., Twigger, K., Diaz, R. M., Thompson, J., Selby, P., de Bono, J., Melcher, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1510 · Cited by 174 · cited 1×
“One method is by using an immunosuppressive agent, such as cyclophosphamide, that has been shown to improve virus spread and anti-tumoral efficacy [139-145].”
MethodSystemic reovirus therapy of metastatic cancer in immune-competent mice.
Hirasawa, K., Nishikawa, S. G., Norman, K. L., Coffey, M. C., Thompson, B., Yoon, C., Waisman, D. M., & Lee, P. W. K. (2003) · PubMed · Cited by 173
Effect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy
Kurozumi, K., Hardcastle, J., Thakur, R., Yang, M., Christoforidis, G., Fulci, G., Hochberg, F. H., Weissleder, R., Carson, W., Chiocca, E. A., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm229 · Cited by 172 · cited 1×
“[146] found that single doses of the angiostatic and anti-inflammatory cyclic peptide of arginine-glycine-aspartic (cRGD), given before an oncolytic HSV, resulted in reduced tumor vessel permeability, leukocyte infiltration and IFN-,”
BackgroundE3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models
Wang, Y., Hallden, G., Hill, R., Anand, A., Liu, T.-C., Francis, J., Brooks, G., Lemoine, N., & Kirn, D. (2003) · Nature Biotechnology · doi:10.1038/nbt887 · Cited by 161 · cited 15×
“Endo et al. [193] showed that virus replication led to the production of uric acid in cancer cells, which stimulated DCs to Viruses 2010, 2 90 produce IFN- and IL-12.”
BackgroundInfluentialSelf-citationAdenovirus Type 5 Interactions with Human Blood Cells May Compromise Systemic Delivery
Lyons, M. J., Onion, D., Green, N. K., Aslan, K., Rajaratnam, R., Bazán‐Peregrino, M., PHIPPS, S. L., Hale, S. J. M., Mautner, V., Seymour, L. W., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.003 · Cited by 156 · cited 1×
“For Ad, adhesion to blood cells could also lead to therapeutic inhibition [138].”
BackgroundAdenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector
Kostense, S., Koudstaal, W., Sprangers, M., Weverling, G. J., Penders, G., Helmus, N., Vogels, R., Bakker, M. E., Berkhout, B., Havenga, M. J. E., et al. (2004) · AIDS · doi:10.1097/00002030-200405210-00019 · Cited by 156
Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy.
Lorence, R. M., Katubig, B. B., Reichard, K. W., Reyes, H. M., Phuangsab, A., Sassetti, M., Walter, R. J., & Peeples, M. E. (1994) · PubMed · Cited by 156
A New Group B Adenovirus Receptor Is Expressed at High Levels on Human Stem and Tumor Cells
Tuve, S., Wang, H., Ware, C., Liu, Y., Gaggar, A., Bernt, K., Shayakhmetov, D., Li, Z., Strauss, R., Stone, D., et al. (2006) · Journal of Virology · doi:10.1128/jvi.01370-06 · Cited by 154 · cited 1×
“[123].”
Schneider, R. J., Safer, B., Munemitsu, S. M., Samuel, C. E., & Shenk, T. E. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.13.4321 · Cited by 152 · cited 3×
“These are RNA polymerase III transcripts that, amongst other functions, are obligatory for efficient translation of viral and cellular mRNAs by blocking the double-stranded RNA-activated protein kinase (PKR) [58,59], a natural host anti-viral defense system (Figure 1).”
BackgroundCawood, R., Chen, H. H., Carroll, F., Bazán‐Peregrino, M., van Rooijen, N., & Seymour, L. W. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000440 · Cited by 151 · cited 1×
“This has been demonstrated by several groups [34-38].”
BackgroundYlösmäki, E. O., Hakkarainen, T., Hemminki, A., Visakorpi, T., Andino, R., & Saksela, K. (2008) · Journal of Virology · doi:10.1128/jvi.01608-08 · Cited by 150 · cited 1×
“This has been demonstrated by several groups [34-38].”
BackgroundQiao, J., Kottke, T. J., Willmon, C. L., Galivo, F., Wongthida, P., Díaz, R. M., Thompson, J., Ryno, P. K., Barber, G. N., Chester, J. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1681 · Cited by 148 · cited 1×
“monocytes [160], outgrowth endothelial cells [160], tumor cells [161-163], T cells [164-166], and dendritic cells (DCs) [165].”
BackgroundHolterman, L., Vogels, R., van der Vlugt, R., Sieuwerts, M., Grimbergen, J., Kaspers, J., Geelen, E., van der Helm, E., Lemckert, A., Gillissen, G., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.23.13207-13215.2004 · Cited by 148 · cited 1×
“to 45-90% for Ad5 [122,153-155].”
Hakkarainen, T., Särkioja, M., Lehenkari, P., Miettinen, S., Ylikomi, T., Suuronen, R., Desmond, R. A., Kanerva, A., & Hemminki, A. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.034 · Cited by 146 · cited 1×
“Cells that have been tested include mesenchymal stem cells [157-159], monocytes [160], outgrowth endothelial cells [160], tumor cells [161-163], T cells [164-166], and dendritic cells (DCs) [165].”
BackgroundChen, Y., Yu, D., Charlton, D., & Henderson, D. (2000) · Human Gene Therapy · doi:10.1089/10430340050083289 · Cited by 143 · cited 1×
“Various data suggest that pre-existing antibodies decrease virus spread after intravenous delivery [147-149], but have a lesser effect on intratumoral injection [44,150,151].”
BackgroundIlett, E. J., Prestwich, R. J. D., Kottke, T. J., Errington‐Mais, F., Thompson, J., Harrington, K. J., Pandha, H., Coffey, M. C., Selby, P. J., Vile, R. G., et al. (2009) · Gene Therapy · doi:10.1038/gt.2009.29 · Cited by 139 · cited 1×
“monocytes [160], outgrowth endothelial cells [160], tumor cells [161-163], T cells [164-166], and dendritic cells (DCs) [165].”
BackgroundIankov, I. D., Blechacz, B. R. A., Liu, C., Schmeckpeper, J., Tarara, J. E., Federspiel, M. J., Caplice, N. M., & Russell, S. J. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300020 · Cited by 137
Mahller, Y. Y., Williams, J. P., Baird, W. H., Mitton, B., Grossheim, J., Saeki, Y., Cancelas, J. A., Ratner, N., & Cripe, T. P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004235 · Cited by 136 · cited 1×
“Evidence has shown that oncolytic Ads are able to destroy these cells [129-131].”
BackgroundDevelopment of adenovirus serotype 35 as a gene transfer vector
Reddy, P. S., Ganesh, S., Limbach, M. P., Brann, T. W., Pinkstaff, A., Kaloss, M., Kaleko, M., & Connelly, S. (2003) · Virology · doi:10.1016/s0042-6822(03)00161-2 · Cited by 136 · cited 1×
“to 45-90% for Ad5 [122,153-155].”
A let-7 MicroRNA-sensitive Vesicular Stomatitis Virus Demonstrates Tumor-specific Replication
Edge, R. E., Falls, T. J., Brown, C. W., Lichty, B. D., Atkins, H., & Bell, J. C. (2008) · Molecular Therapy · doi:10.1038/mt.2008.130 · Cited by 135 · cited 1×
“This has been demonstrated by several groups [34-38].”
BackgroundLi, J., Liu, H., Xr, Z., Xu, J.-P., Hu, W.-K., Liang, M., Chen, S.-Y., Hu, F., & Chu, D.-T. (2008) · Gene Therapy · doi:10.1038/gt.2008.179 · Cited by 132 · cited 1×
“Recent examples include the heat shock proteins [179,180], chemokine (C-C motif) ligand 5 (CCL5) [181], IFN [182], granulocyte macrophage colony-stimulating factor (GM-CSF) [183-185], IL-12 [186], IL-18 [81,82], and IL-24 [187,188].”
BackgroundAdenovirus E1B 55-Kilodalton Protein: Multiple Roles in Viral Infection and Cell Transformation
Blackford, A. N., & Grand, R. J. A. (2009) · Journal of Virology · doi:10.1128/jvi.02417-08 · Cited by 132 · cited 1×
“The E1B 55K protein is involved in p53 inhibition, viral mRNA transport and host cell protein synthesis shut-off [42] (Figure 2), whilst E3B proteins are important for immune avoidance”
BackgroundWillmon, C. L., Saloura, V., Fridlender, Z. G., Wongthida, P., Díaz, R. M., Thompson, J., Kottke, T. J., Federspiel, M. J., Barber, G. N., Albelda, S. Μ., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1013 · Cited by 131 · cited 1×
“Recent examples include the heat shock proteins [179,180], chemokine (C-C motif) ligand 5 (CCL5) [181], IFN [182], granulocyte macrophage colony-stimulating factor (GM-CSF) [183-185], IL-12 [186], IL-18 [81,82], and IL-24 [187,188].”
BackgroundOng, H. T., Hasegawa, K., Dietz, A. B., Russell, S. J., & Peng, K.-W. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302880 · Cited by 131 · cited 1×
“[167] showed that MV-infected T cells could facilitate tumoral delivery in low, but not high antibody concentration.”
BackgroundEffects of innate immunity on herpes simplex virus and its ability to kill tumor cells
Wakimoto, H., Johnson, P. R., Knipe, D., & Chiocca, E. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302038 · Cited by 130 · cited 1×
“It appears that the innate immune response plays an important role in virus clearance, whereas T cell-mediated responses are largely responsible for the anti-tumoral effect [133-137].”
BackgroundAdenovirus VAI RNA facilitates the initiation of translation in virus-infected cells
Schneider, R. J., Weinberger, C., & Shenk, T. E. (1984) · Cell · doi:10.1016/0092-8674(84)90325-8 · Cited by 127 · cited 3×
“These are RNA polymerase III transcripts that, amongst other functions, are obligatory for efficient translation of viral and cellular mRNAs by blocking the double-stranded RNA-activated protein kinase (PKR) [58,59], a natural host anti-viral defense system (Figure 1).”
BackgroundWakimoto, H., Fulci, G., Tyminski, E., & Chiocca, E. A. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302143 · Cited by 127 · cited 1×
“One method is by using an immunosuppressive agent, such as cyclophosphamide, that has been shown to improve virus spread and anti-tumoral efficacy [139-145].”
MethodHuang, J.-H., Zhang, S.-N., Choi, K., Choi, I.-K., Kim, J.-H., Lee, M., Kim, H., & Yun, C. (2009) · Molecular Therapy · doi:10.1038/mt.2009.205 · Cited by 124 · cited 1×
“[197] utilized an oncolytic Ad armed with IL-12 and 4-1BB ligand, and demonstrated impressive results in mice bearing B16-F10 melanoma tumors.”
BackgroundGanly, I., Eckhardt, S. G., Rodriguez, G. I., Soutar, D. S., Otto, R. A., Robertson, A. G., Park, O., Gulley, M. L., Heise, C. O., Hoff, D. D. V., et al. (2000) · Clinical Cancer Research · Cited by 122
McSharry, B. P., Burgert, H.-G., Owen, D. P., Stanton, R. J., Prod’homme, V., Sester, M., Koebernick, K., Groh, V., Spies, T. A., Cox, S. T., et al. (2008) · Journal of Virology · doi:10.1128/jvi.02251-07 · Cited by 121
Foloppe, J., Kintz, J., Futin, N., Findeli, A., Cordier, P., Schlesinger, Y., Hoffmann, C., Tosch, C., Balloul, J.-M., & Erbs, P. (2008) · Gene Therapy · doi:10.1038/gt.2008.82 · Cited by 119 · cited 1×
“Alternative combinations include nitroreductase with the prodrug CB1954 (converted into an alkylating agent) [94], and cytosine deaminase (CD) with 5-fluorocytosine, which is converted into the cytotoxic and radiosensitizing 5-fluorouracil [95,96].”
BackgroundAnders, M., Christian, C., McMahon, M., McCormick, F. P., & Korn, W. M. (2003) · PubMed · Cited by 117
Thomas, M., Spencer, J. F., Tóth, K., Sagartz, J. E., Phillips, N. J., & Wold, W. S. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.162 · Cited by 117 · cited 1×
“One method is by using an immunosuppressive agent, such as cyclophosphamide, that has been shown to improve virus spread and anti-tumoral efficacy [139-145].”
MethodE1B 19K Inhibits Fas-mediated Apoptosis through FADD-dependent Sequestration of FLICE
Perez, D., & White, E. P. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.5.1255 · Cited by 116 · cited 1×
“spread [51,52], adenoviral E1B 19K is a functional homolog of Bcl-2 and is able to bind to Bax [53-55] and also prevent Fas-mediated apoptosis [56].”
BackgroundLee, C., Rennie, P. S., & Jia, W. W.-G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0051 · Cited by 113 · cited 1×
“This has been demonstrated by several groups [34-38].”
BackgroundGanesh, S., Gonzalez-Edick, M., Gibbons, D., Roey, M. V., & Jooss, K. U. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4732 · Cited by 113 · cited 1×
“[98] studied the co-administration of the enzyme hyaluronidase with oncolytic Ads during intratumoral injection.”
BackgroundDoronin, K., Shashkova, E. V., May, S. M., Hofherr, S. E., & Barry, M. A. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.028 · Cited by 112 · cited 1×
“molecular weight polyethylene glycol [176] or by genetic modification of the hexon protein to ablate blood factor binding [177] for liver detargeting.”
BackgroundCoukos, G., Makrigiannakis, A., Kang, E. H., Caparelli, D., Benjamin, I., Kaiser, L. R., Rubin, S. C., Albelda, S. Μ., & Molnar-Kimber, K. L. (1999) · PubMed · Cited by 108
Bortolanza, S., Buñuales, M., Otano, I., González‐Aseguinolaza, G., Ortíz-de-Solórzano, C., Perez, D., Prìeto, J., & Hernández-Alcoceba, R. (2009) · Molecular Therapy · doi:10.1038/mt.2009.9 · Cited by 108
Morrison, J., Briggs, S. S., Green, N. H., Fisher, K. D., Šubr, V., Ulbrich, K., Kehoe, S. T., & Seymour, L. W. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300363 · Cited by 106 · cited 1×
“expression of cell surface receptors unique to cancer cells [14-20].”
BackgroundCancer Cell Death Enhances the Penetration and Efficacy of Oncolytic Herpes Simplex Virus in Tumors
Nagano, S., Perentes, J. Y., Jain, R. K., & Boucher, Y. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6193 · Cited by 104 · cited 1×
“Induction of cancer cell death with an apoptosis-inducing agent prior to injection of oncolytic HSV could also produce channels for effective virus spread [99].”
BackgroundOncolytic Adenoviruses Kill Breast Cancer Initiating CD44+CD24–/Low Cells
Eriksson, M. R., Guse, K., Bauerschmitz, G. J., Virkkunen, P. J., Tarkkanen, M., Tanner, M., Hakkarainen, T., Kanerva, A., Desmond, R. A., Pesonen, S. A., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300300 · Cited by 104 · cited 1×
“Evidence has shown that oncolytic Ads are able to destroy these cells [129-131].”
BackgroundZamarin, D., Martínez‐Sobrido, L., Kelly, K. J., Mansour, M., Sheng, G., Vigil, A., García‐Sastre, A., Palese, P., & Fong, Y. (2009) · Molecular Therapy · doi:10.1038/mt.2008.286 · Cited by 102 · cited 1×
“It appears that the innate immune response plays an important role in virus clearance, whereas T cell-mediated responses are largely responsible for the anti-tumoral effect [133-137].”
BackgroundDevelopment and Assessment of Human Adenovirus Type 11 as a Gene Transfer Vector
Stone, D., Ni, S., Li, Z.-Y., Gaggar, A., DiPaolo, N., Feng, Q., Sandig, V., & Lieber, A. (2005) · Journal of Virology · doi:10.1128/jvi.79.8.5090-5104.2005 · Cited by 102 · cited 3×
“Besides CD46, evidence suggests that the subgroup B Ad, Ad11, also utilizes another unidentified receptor [121,122], tentatively named ‘receptor X’ by Tuve et al.”
BackgroundYoo, J. Y., Kim, J.-H., Kim, J., Huang, J.-H., Zhang, S.-N., Kang, Y.-A., Kim, H., & Yun, C.-O. (2008) · Gene Therapy · doi:10.1038/gt.2008.3 · Cited by 100 · cited 3×
“Yoo, J.Y.; Kim, J.H.; Kim, J.; Huang, J.H.; Zhang, S.N.; Kang, Y.A.; Kim, H.; Yun, C.O. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition.”
BackgroundShashkova, E. V., Doronin, K., Senac, J. S., & Barry, M. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0488 · Cited by 99 · cited 1×
“replicating Ad5) and warfarin treatment (to inhibit vitamin K-dependent coagulation factors) and found that this approach significantly increased the anti-tumoral effect of systemically delivered oncolytic Ad5 in nude mice [175].”
BackgroundZhang, X., Komaki, R. K., Wang, L., Fang, B., & Chang, J. Y. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1528 · Cited by 99 · cited 1×
“[132] have recently demonstrated that a telomerase-specific oncolytic Ad armed with a gene that encodes the”
BackgroundChang, J., Zhao, X., Wu, X., Guo, Y., Guo, H., Cao, J., Guo, Y., Lou, D., Yu, D., & Li, J. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.8.7913 · Cited by 96 · cited 1×
“Recent examples include the heat shock proteins [179,180], chemokine (C-C motif) ligand 5 (CCL5) [181], IFN [182], granulocyte macrophage colony-stimulating factor (GM-CSF) [183-185], IL-12 [186], IL-18 [81,82], and IL-24 [187,188].”
BackgroundMurray, K. P., Mathure, S., Kaul, R., Khan, S., Carson, L. F., Twiggs, L. B., Martens, M. G., & Kaul, A. (2000) · Gynecologic Oncology · doi:10.1006/gyno.1999.5614 · Cited by 94 · cited 1×
“In contrast, most subgroup B Ads bind to CD46 [110], a receptor often upregulated in a number of tumor types, including breast, cervical, liver, lung, endometrial and hematological malignancies [111-113].”
BackgroundEndo, Y., Sakai, R., Ouchi, M., Onimatsu, H., Hioki, M., Kagawa, S., Uno, F., Watanabe, Y., Urata, Y., Tanaka, N., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210884 · Cited by 94 · cited 1×
“[193] showed that virus replication led to the production of uric acid in cancer cells, which stimulated DCs to”
BackgroundMahller, Y. Y., Vaikunth, S. S., Ripberger, M. C., Baird, W. H., Saeki, Y., Cancelas, J. A., Crombleholme, T. M., & Cripe, T. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2734 · Cited by 94 · cited 1×
“viruses armed with genes that encode MMP inhibitors have shown encouraging results in delaying tumor growth and angiogenesis [89,90].”
BackgroundArmed replicating adenoviruses for cancer virotherapy
Cody, J. J., & Douglas, J. T. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.3 · Cited by 94 · cited 1×
“Gene-manipulated oncolytic viruses such as Ad, herpes virus and vaccinia virus are being developed as a new class of anti-tumoral agent [23,40,41].”
BackgroundEngineering Oncolytic Measles Virus to Circumvent the Intracellular Innate Immune Response
Haralambieva, I. H., Iankov, I. D., Hasegawa, K., Harvey, M. E., Russell, S. J., & Peng, K.-W. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300076 · Cited by 92 · cited 1×
“Recombinant MV encoding the measles phosphoprotein (P) gene product from wild-type MV, an IFN antagonist, has been found to exhibit reduced IFN sensitivity and better oncolytic potency in vivo [191].”
BackgroundLapteva, N., Aldrich, M. B., Weksberg, D. C., Rollins, L. A., Goltsova, T., Chen, S. Y., & Huang, X. F. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318193d31e · Cited by 92 · cited 2×
“Recent examples include the heat shock proteins [179,180], chemokine (C-C motif) ligand 5 (CCL5) [181], IFN [182], granulocyte macrophage colony-stimulating factor (GM-CSF) [183-185], IL-12 [186], IL-18 [81,82], and”
BackgroundE1B 19K Blocks Bax Oligomerization and Tumor Necrosis Factor Alpha-Mediated Apoptosis
Sundararajan, R., & White, E. (2001) · Journal of Virology · doi:10.1128/jvi.75.16.7506-7516.2001 · Cited by 89 · cited 5×
“In addition to its effect on virus release and Viruses 2010, 2 83 spread [51,52], adenoviral E1B 19K is a functional homolog of Bcl-2 and is able to bind to Bax [53-55] and also prevent Fas-mediated apoptosis [56].”
BackgroundInfluentialRas-dependent oncolysis with an adenovirus VAI mutant.
Cascalló, M., Capellá, G., Mazo, A., & Alemany, R. (2003) · PubMed · Cited by 88
Herrlinger, U., Kramm, C., Aboody-Guterman, K., Silver, J. S., Ikeda, K., Johnston, K., Pechan, P., Barth, R., Finkelstein, D., Chiocca, E., et al. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300643 · Cited by 87
Oncolytic HSV-1 Infection of Tumors Induces Angiogenesis and Upregulates CYR61
Kurozumi, K., Hardcastle, J., Thakur, R., Shroll, J., Nowicki, M., Otsuki, A., Chiocca, E. A., & Kaur, B. (2008) · Molecular Therapy · doi:10.1038/mt.2008.112 · Cited by 86 · cited 1×
“[76] also showed that intratumoral treatment of rat glioma with oncolytic HSV could promote neovascularization of the residual tumor, and this was associated with a significant increase in the angiogenic factor CYR61.”
BackgroundEffect of hypoxia on Ad5 infection, transgene expression and replication
Shen, B. H., & Hermiston, T. W. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302448 · Cited by 86 · cited 1×
“feature in tumor tissues, has been found to reduce the replicative and oncolytic potential of Ads despite the unaltered expression of surface receptors [103,104].”
BackgroundAltomonte, J., Wu, L., Meseck, M. L., Chen, L. A., Ebert, O., García‐Sastre, A., Fallon, J. T., Mandeli, J., & Woo, S. L. C. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.74 · Cited by 86 · cited 1×
“A recombinant VSV vector which expresses a gene from human CMV has been found to have increased anti-tumoral activity in vivo [192].”
BackgroundLiu, T., Halldén, G., Wang, Y., Brooks, G., Francis, J., Lemoine, N., & Kirn, D. H. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.03.017 · Cited by 82 · cited 4×
“Jin et al. [68] and Chen et al. [69] utilized the chimeric Ad5/35 carrying the gene encoding the TNF-related apoptosis-inducing ligand (TRAIL) to promote receptor-independent infection (see below) and apoptosis of leukemic and gastric cancer cells, respectively.”
BackgroundInfluentialSelf-citationVähä-Koskela, M. J. V., Kallio, J. P., Jansson, L. C., Heikkilä, J., Zakhartchenko, V. A., Kallajoki, M. A., Kähäri, V., & Hinkkanen, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2214 · Cited by 81 · cited 1×
“virus [205], and Semliki Forest virus [206].”
Tsai, V., Johnson, D. E., Rahman, A., Wen, S. F., LaFace, D., Philopena, J. M., Nery, J., Zepeda, M. L., Maneval, D. C., Demers, G. W., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0765 · Cited by 80 · cited 1×
“Various data suggest that pre-existing antibodies decrease virus spread after intravenous delivery [147-149], but have a lesser effect on intratumoral injection [44,150,151].”
BackgroundGenetic Identification of Adenovirus Type 5 Genes That Influence Viral Spread
Subramanian, T., Vijayalingam, S., & Chinnadurai, G. (2006) · Journal of Virology · doi:10.1128/jvi.80.4.2000-2012.2006 · Cited by 80 · cited 1×
“spread [51,52], adenoviral E1B 19K is a functional homolog of Bcl-2 and is able to bind to Bax [53-55] and also prevent Fas-mediated apoptosis [56].”
BackgroundAllen, C., Paraskevakou, G., Iankov, I. D., Giannini, C., Schroeder, M. A., Sarkaria, J. N., Puri, R. K., Russell, S. J., & Galanis, E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.152 · Cited by 79 · cited 1×
“expression of cell surface receptors unique to cancer cells [14-20].”
BackgroundInterferon resistance promotes oncolysis by influenza virus NS1‐deletion mutants
Muster, T., Rajtarova, J., Sachet, M., Unger, H., Fleischhacker, R., Romirer, I., Grassauer, A., Url, A., García‐Sastre, A., Wolff, K. S., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20078 · Cited by 79 · cited 1×
“The influenza virus NS1-deleted mutant is also dependent on this defective pathway [26].”
BackgroundChalikonda, S., Kivlen, M. H., O’Malley, M. E., Dong, X., McCart, J. A., Gorry, M. C., Yin, X.-Y., Brown, C., Zeh, H. J., Guo, Z. S., et al. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701110 · Cited by 78 · cited 1×
“Alternative combinations include nitroreductase with the prodrug CB1954 (converted into an alkylating agent) [94], and cytosine deaminase (CD) with 5-fluorocytosine, which is converted into the cytotoxic and radiosensitizing 5-fluorouracil [95,96].”
BackgroundLiu, T., Castelo‐Branco, P., Rabkin, S. D., & Martuza, R. L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.58 · Cited by 76 · cited 1×
“and trichostatin A [84], as well as arming viruses with genes that inhibit pro-angiogenic molecules such as IL-8 [85] and vascular endothelial growth factor (VEGF) [86,87].”
BackgroundEpithelial Phenotype Confers Resistance of Ovarian Cancer Cells to Oncolytic Adenoviruses
Strauss, R., Sova, P., Liu, Y., Li, Z. Y., Tuve, S., Pritchard, D. K., Brinkkoetter, P. T., Möller, T. B., Wildner, O., Pesonen, S. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0645 · Cited by 75 · cited 1×
“[125] showed that Ads that utilize CAR or CD46 as primary attachment receptors failed to infect and lyse ovarian cancer cells of the epithelial phenotype, which are found in in situ tumors and tumor xenografts.”
BackgroundHypoxia Enhances the Replication of Oncolytic Herpes Simplex Virus
Aghi, M. K., Liu, T., Rabkin, S. D., & Martuza, R. L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.232 · Cited by 75 · cited 1×
“virus [105] or HSV [106,107].”
Dhar, D., Spencer, J. F., Tóth, K., & Wold, W. S. M. (2008) · Journal of Virology · doi:10.1128/jvi.02127-08 · Cited by 73 · cited 1×
“Various data suggest that pre-existing antibodies decrease virus spread after intravenous delivery [147-149], but have a lesser effect on intratumoral injection [44,150,151].”
BackgroundCoughlan, L., Vallath, S., Saha, A., Flak, M. B., McNeish, I. A., Vassaux, G., Marshall, J. F., Hart, I. R., & Thomas, G. J. (2009) · Journal of Virology · doi:10.1128/jvi.00445-09 · Cited by 71 · cited 1×
“expression of cell surface receptors unique to cancer cells [14-20].”
BackgroundCharacterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents
Shashkova, E. V., May, S. M., & Barry, M. A. (2009) · Virology · doi:10.1016/j.virol.2009.08.038 · Cited by 71 · cited 3×
“This provides a further rationale for the development of other Ad serotypes for oncolytic therapy, such as Ad11 and Ad35 as they bind weakly to factor X compared to Ad5 [118] or other Ad5 chimera.”
BackgroundTysome, J. R., Briat, A., Alusi, G., Cao, F., Gao, D., Yu, J., Wang, P., Yang, S., Dong, Z., Wang, S., et al. (2009) · Gene Therapy · doi:10.1038/gt.2009.74 · Cited by 71 · cited 1×
“Recent work includes the use of the anti-angiogenic factors endostatin/angiostatin [78-80], interleukin-18 (IL-18) [81,82], canstatin [83],”
BackgroundSelf-citationGomes, E. M., Rodrigues, M. S., Phadke, A. P., Butcher, L. D., Starling, C. E., Chen, S., Chang, D., Hernández-Alcoceba, R., Newman, J. T., Stone, M. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1360 · Cited by 70 · cited 1×
“expression of cell surface receptors unique to cancer cells [14-20].”
BackgroundEdukulla, R., Woller, N., Mundt, B., Knocke, S., Gürlevik, E., Saborowski, M., Malek, N. P., Manns, M. P., Wirth, T. C., Kühnel, F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1160 · Cited by 69 · cited 1×
“[195] demonstrated that increased DC migration and maturation by oncolytic Ad encoding β-defensin-2 or macrophage inflammatory protein 1α (MIP-1α) and Fms-like tyrosine kinase-3 ligand (Flt3L) significantly enhanced anti-tumoral immune responses.”
BackgroundLister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours
Hiley, C. T., Yuan, M., Lemoine, N. R., & Wang, Y. (2009) · Gene Therapy · doi:10.1038/gt.2009.132 · Cited by 69
Self-citationWang, X., Su, C., Cao, H., Li, K., Chen, J., Jiang, L., Zhang, Q., Wu, X., Jia, X., Liu, Y., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2429 · Cited by 66 · cited 1×
“[65] developed an Ad in which the E1A gene is regulated by the human telomerase reverse transcriptase (hTERT) promoter and hypoxia response element, together with p53 under the strong cytomegalovirus (CMV) promoter.”
BackgroundCarrier cell‐mediated delivery of oncolytic parvoviruses for targeting metastases
Raykov, Z., Balboni, G., Aprahamian, M., & Rommelaere, J. (2004) · International Journal of Cancer · doi:10.1002/ijc.20013 · Cited by 64 · cited 1×
“monocytes [160], outgrowth endothelial cells [160], tumor cells [161-163], T cells [164-166], and dendritic cells (DCs) [165].”
BackgroundHermiston, T. W., Tripp, R. A., Sparer, T. E., Gooding, L. R., & Wold, W. S. M. (1993) · Journal of Virology · doi:10.1128/jvi.67.9.5289-5298.1993 · Cited by 63 · cited 4×
“In addition to the inhibition of NK cell activation [200], gp19K is an endoplasmic reticulum membrane glycoprotein that inhibits the transport of MHC class I to the cell surface and delays its expression to avoid killing by CTLs [201,202].”
BackgroundInfluentialComparison of Adenoviruses From Species B, C, E, and F After Intravenous Delivery
Stone, D., Liu, Y., Li, Z.-Y., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300319 · Cited by 61 · cited 3×
“In CD46 transgenic mice, Ad11 persisted much longer in the circulation after intravenous delivery compared to Ad5 together with the absence of liver transduction [120,122].”
BackgroundIn vivoeffects of targeting CD79b with antibodies and antibody-drug conjugates
Zheng, B., Fuji, R. N., Elkins, K., Yu, S., Fuh, F. K., Chuh, J., Tan, C., Hongo, J.-A., Raab, H. E., Kozak, K. R., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0369 · Cited by 60
Attraction and Activation of Dendritic Cells at the Site of Tumor Elicits Potent Antitumor Immunity
Lapteva, N., Aldrich, M. B., Rollins, L. A., Ren, W., Goltsova, T., Chen, S.-Y., & Huang, X. F. (2009) · Molecular Therapy · doi:10.1038/mt.2009.111 · Cited by 58 · cited 1×
“[194] and Ramakrishna et al.”
Lei, N., Shen, F., Chang, J. H., Wang, L., Li, H., Yang, C., Li, J., & Yu, D. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.46 · Cited by 58 · cited 3×
“Recent examples include the heat shock proteins [179,180], chemokine (C-C motif) ligand 5 (CCL5) [181], IFN [182], granulocyte macrophage colony-stimulating factor (GM-CSF) [183-185], IL-12 [186], IL-18 [81,82], and”
BackgroundCell carriers to deliver oncolytic viruses to sites of myeloma tumor growth
Munguia, A., Ota, T., Miest, T. S., & Russell, S. J. (2008) · Gene Therapy · doi:10.1038/gt.2008.45 · Cited by 58 · cited 1×
“monocytes [160], outgrowth endothelial cells [160], tumor cells [161-163], T cells [164-166], and dendritic cells (DCs) [165].”
BackgroundChu, L., Gu, J., Sun, L., Qian, Q., Qian, C., & Liu, X. (2008) · Gene Therapy · doi:10.1038/gt.2008.6 · Cited by 58 · cited 2×
“Recent work includes those targeting hTERT [71], Ki-67 [72], Survivin [73], and Apollon [74], all of which have shown efficient anti-tumoral effects in vitro and in vivo.”
BackgroundKang, Y.-A., Shin, H.-C., Yoo, J. Y., Kim, J.-H., Kim, J.-H., Kim, J., Kim, J., & Yun, C. (2008) · Molecular Therapy · doi:10.1038/mt.2008.63 · Cited by 55 · cited 1×
“[88] made use of a transcriptional repressor based on zinc-finger protein to target the VEGF promoter.”
Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity
Piao, Y., Jiang, H., Alemany, R., Krasnykh, V. N., Marini, F. C., Xu, J., Alonso, M. M., Conrad, C. A., Aldape, K., Gomez‐Manzano, C., et al. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.75 · Cited by 50 · cited 1×
“, Coxsackievirus A21 [12] and measles virus (MV) [13]) or have been designed to have specific tropism based on the expression of cell surface receptors unique to cancer cells [14-20].”
BackgroundLuo, J., Xia, Q., Zhang, R., Lv, C., Zhang, W., Wang, Y., Cui, Q., Liu, L., Cai, R., & Qian, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4596 · Cited by 48 · cited 1×
“Recent examples include the heat shock proteins [179,180], chemokine (C-C motif) ligand 5 (CCL5) [181], IFN [182], granulocyte macrophage colony-stimulating factor (GM-CSF) [183-185], IL-12 [186], IL-18 [81,82], and IL-24 [187,188].”
BackgroundSelf-citationZheng, X., Rao, X., Gómez-Gutiérrez, J. G., Hao, H., McMasters, K. M., & Zhou, H. S. (2008) · Journal of Virology · doi:10.1128/jvi.01708-07 · Cited by 47 · cited 1×
“E overexpression [32], and E1B 55K-independent late viral RNA export in cancer but not normal cells [33].”
BackgroundSung, B., Pandey, M. K., Nakajima, Y., Nishida, H., Konishi, T., Chaturvedi, M. M., & Aggarwal, B. B. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0406 · Cited by 45
Dhar, D., Spencer, J. F., Tóth, K., & Wold, W. S. M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.156 · Cited by 44 · cited 1×
“Although antibodies could prevent possible toxicity [152], they”
BackgroundZheng, J.-N., Pei, D.-S., Lj, M., Liu, X., Sun, F.-H., Bf, Z., Liu, Y.-Q., Liu, J.-J., Li, W., & Han, D. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.38 · Cited by 44 · cited 4×
“Recent examples include the heat shock proteins [179,180], chemokine (C-C motif) ligand 5 (CCL5) [181], IFN [182], granulocyte macrophage colony-stimulating factor (GM-CSF) [183-185], IL-12 [186], IL-18 [81,82], and”
BackgroundInfluentialKolodkin‐Gal, D., Zamir, G. A., Edden, Y., Pikarsky, E., Pikarsky, A. J., Haim, H., Haviv, Y. S., & Panet, A. (2007) · Journal of Virology · doi:10.1128/jvi.01769-07 · Cited by 43
Nishimoto, T., Yoshida, K., Miura, Y., Kobayashi, A., Hara, H., Ohnami, S., Kurisu, K., Yoshida, T., & Aoki, K. (2009) · Gene Therapy · doi:10.1038/gt.2009.1 · Cited by 43
Conner, J., Braidwood, L., & Brown, S. M. (2008) · Gene Therapy · doi:10.1038/gt.2008.121 · Cited by 42 · cited 1×
“expression of cell surface receptors unique to cancer cells [14-20].”
BackgroundUtilizing Ras Signaling Pathway to Direct Selective Replication of Herpes Simplex Virus-1
Pan, W., Bodempudi, V., Esfandyari, T., & Farassati, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006514 · Cited by 39 · cited 1×
“This can be achieved by the insertion of a tumor-specific promoter driving the expression of a critical gene [5-11].”
BackgroundE4orf1 Limits the Oncolytic Potential of the E1B - 55K Deletion Mutant Adenovirus
Thomas, M. A., Broughton, R. S., Goodrum, F. D., & Ornelles, D. A. (2009) · Journal of Virology · doi:10.1128/jvi.01972-08 · Cited by 39 · cited 1×
“[49] revealed that dl1520 was less efficient in lysing cells infected in the G1 phase of the cell cycle due to a reduced rate of late viral protein synthesis, and”
BackgroundTumor Antigen LRRC15 Impedes Adenoviral Infection: Implications for Virus-Based Cancer Therapy
O’Prey, J., Wilkinson, S., & Ryan, K. M. (2008) · Journal of Virology · doi:10.1128/jvi.02273-07 · Cited by 39 · cited 1×
“repeat-containing protein 15 (LRRC15 or hLib), frequently overexpressed in tumor cells, could result in the redistribution of CAR away from cell surfaces, thus impeding Ad infection [109].”
BackgroundHuch, M., Gros, A., José, A., González, J. R., Alemany, R., & Fillat, C. (2009) · Neoplasia · doi:10.1593/neo.81674 · Cited by 38 · cited 1×
“This can be achieved by the insertion of a tumor-specific promoter driving the expression of a critical gene [5-11].”
BackgroundExpanded Anticancer Therapeutic Window of Hexon-modified Oncolytic Adenovirus
Shashkova, E. V., May, S. M., Doronin, K., & Barry, M. A. (2009) · Molecular Therapy · doi:10.1038/mt.2009.217 · Cited by 38 · cited 1×
“molecular weight polyethylene glycol [176] or by genetic modification of the hexon protein to ablate blood factor binding [177] for liver detargeting.”
BackgroundDownregulation of human CD46 by adenovirus serotype 35 vectors
Sakurai, F., Akitomo, K., Kawabata, K., Hayakawa, T., & Mizuguchi, H. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302946 · Cited by 37 · cited 11×
“Besides CD46, evidence suggests that the subgroup B Ad, Ad11, also utilizes another unidentified receptor [121,122], tentatively named ‘receptor X’ by Tuve et al. [123].”
BackgroundInfluentialBortolanza, S., Buñuales, M., Alzuguren, P., Lamas, Ó., Aldabe, R., Prìeto, J., & Hernández-Alcoceba, R. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.12 · Cited by 36 · cited 1×
“Potency could be restored by selective deletion of E3 gp19K whilst retaining other E3 regions [133,199].”
BackgroundLiu, T.-C., Wang, Y., Halldén, G., Brooks, G., Francis, J., Lemoine, N. R., & Kirn, D. H. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302555 · Cited by 34 · cited 2×
“In addition to its effect on virus release and spread [51,52], adenoviral E1B 19K is a functional homolog of Bcl-2 and is able to bind to Bax [53-55] and also prevent Fas-mediated apoptosis [56].”
BackgroundSelf-citationCEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells
Wang, Y., Gangeswaran, R., Zhao, X., Wang, P., Tysome, J. R., Bhakta, V., Yuan, M., Chikkanna-Gowda, C. P., Jiang, G., Gao, D., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37905 · Cited by 33
Self-citationHe, X., Su, C., Wang, X., Pan, X., Tu, Z., Gong, Y.-F., Gao, J., Liao, Z., Jin, J., Wu, H., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.05.006 · Cited by 31 · cited 1×
“Recent work includes the use of the anti-angiogenic factors endostatin/angiostatin [78-80], interleukin-18 (IL-18) [81,82], canstatin [83],”
BackgroundSu, C., Na, M., Chen, J., Wang, X., Liu, Y., Wang, W., Zhang, Q., Li, L., Long, J., Liu, X., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0073 · Cited by 29 · cited 1×
“Recent work includes the use of the anti-angiogenic factors endostatin/angiostatin [78-80], interleukin-18 (IL-18) [81,82], canstatin [83],”
BackgroundHu, W., Hofstetter, W. L., Guo, W., Li, H., Pataer, A., Peng, H., Guo, Z. S., Bartlett, D. L., Lin, A., Swisher, S. G., et al. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.32 · Cited by 28 · cited 1×
“activated c-Jun NH2-terminal kinase (JNK) signaling cascade could activate PKR (Figure 1), thus reducing virus replication [128].”
BackgroundHu, Z., Robbins, J. S., Pister, A., Zafar, M. B., Zhang, Z., Gupta, J., Lee, K. J., Neuman, K., Yun, C.-O., Guise, T. A., et al. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.72 · Cited by 27 · cited 1×
“[67].”
Doloff, J. C., Waxman, D. J., & Jounaïdi, Y. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.056 · Cited by 26 · cited 1×
“This can be achieved by the insertion of a tumor-specific promoter driving the expression of a critical gene [5-11].”
BackgroundLin, C., Chen, D., Gong, M., Na, M., Li, L., Wu, H., Jiang, L., Qian, Y., Fang, G., & Xue, X. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.04.026 · Cited by 26 · cited 2×
“Several chimeric oncolytic Ad5 have been developed to contain the fiber tropism of subgroup B Ads and they all have shown encouraging results [68,69,114-117].”
MethodResultA Novel Antiangiogenic Effect for Telomerase-Specific Virotherapy through Host Immune System
Ikeda, Y., Kojima, T., Kuroda, S., Endo, Y., Sakai, R., Hioki, M., Kishimoto, H., Uno, F., Kagawa, S., Watanabe, Y., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1763 · Cited by 23
Fukuda, K., Abei, M., Ugai, H., Kawashima, R., Seo, E., Wakayama, M. I. I., Murata, T., Endo, S., Hamada, H., Hyodo, I., et al. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.67 · Cited by 22
A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy
Nandi, S., Ulasov, I. V., Rolle, C. E., Han, Y., & Lesniak, M. S. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1385 · Cited by 22 · cited 1×
“Several chimeric oncolytic Ad5 have been developed to contain the fiber tropism of subgroup B Ads and they all have shown encouraging results [68,69,114-117].”
ResultShiina, M., Lacher, M. D., Christian, C., & Korn, W. M. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.29 · Cited by 21 · cited 1×
“[127] showed that siRNA knockdown of p21”
Robinson, M., Ge, Y., Ko, D., Yendluri, S., Laflamme, G., Hawkins, L., & Jooss, K. U. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701093 · Cited by 21 · cited 1×
“many adenoviral mutants to provide more space for therapeutic gene insertion, although recent work has suggested that transgene expression was higher if gene was inserted at regions other than E3, such as L3 [198].”
BackgroundMcNally, L. R., Rosenthal, E. L., Zhang, W., & Buchsbaum, D. J. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.76 · Cited by 17 · cited 1×
“viruses armed with genes that encode MMP inhibitors have shown encouraging results in delaying tumor growth and angiogenesis [89,90].”
BackgroundTelomerase-specific virotherapy in an animal model of human head and neck cancer
Nakajima, O., Matsunaga, A., Ichimaru, D., Urata, Y., Fujiwara, T., & Kawakami, K. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0620 · Cited by 14 · cited 1×
“This can be achieved by the insertion of a tumor-specific promoter driving the expression of a critical gene [5-11].”
BackgroundBiological Therapy with Oncolytic Herpesvirus
Benencia, F., & Coukos, G. (2008) · Springer eBooks · doi:10.1007/978-0-387-68969-2_18 · Cited by 10 · cited 1×
“Gene-manipulated oncolytic viruses such as Ad, herpes virus and vaccinia virus are being developed as a new class of anti-tumoral agent [23,40,41].”
BackgroundVijayalingam, S., Subramanian, T., Ryerse, J. S., Varvares, M. A., & Chinnadurai, G. (2009) · Virology · doi:10.1016/j.virol.2009.06.048 · Cited by 9
Cited by
Barish, S., Ochs, M. F., Sontag, E. D., & Gevertz, J. L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703355114 · Cited by 48
Metadata
- Authors
- Wong, H. H., Lemoine, N. R., & Wang, Y.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2010-01-11
- Volume
- 2
- Issue
- 1
- Pages
- 78-106
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W2120963951
- Cited by
- 180
- References
- 165
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.